Eli Lilly has reached a $2.75 billion agreement with Insilico Medicine to develop and commercialize drugs discovered using artificial intelligence. The deal includes $115 million in upfront payments, with additional milestones and royalties tied to regulatory approvals and future sales.
Insilico has built a pipeline of at least 28 drug candidates using generative AI technologies, with nearly half already in clinical stages. The company uses AI models to accelerate drug discovery by identifying molecular targets and generating potential compounds more efficiently than traditional methods.
The partnership builds on an existing relationship between the two companies, which began with a software licensing agreement in 2023. As part of the collaboration, Insilico will join Lilly’s Gateway Labs ecosystem, enabling closer integration across research, development, and commercialization workflows.
Executives from both companies emphasized the complementary nature of the collaboration. While Insilico brings AI-driven discovery capabilities, Eli Lilly contributes expertise in clinical development, regulatory processes, and global distribution.
The deal reflects growing interest in AI-powered drug discovery, as pharmaceutical companies seek to reduce development timelines and improve success rates. Insilico’s model allows faster molecule design and testing, potentially lowering costs and accelerating the transition from research to clinical trials.
The agreement also highlights the global nature of AI-driven biotech, with Insilico conducting research across multiple regions while maintaining ties to China for early-stage development. As AI adoption expands in life sciences, partnerships like this are expected to play a central role in reshaping how new therapies are discovered and brought to market.
